证券代码：838275 证券简称：驱动力 公告编号：2023-007 三、风险提示 本次入选不会对公司当期经营业绩产生重大影响，敬请广大投资者理性投资， 注意投资风险。 四、备查文件 1、《广东省工业和信息化厅关于公布2022年度专精特新中小企业和2019年到期复 核通过企业名单的通告》。 广东驱动力生物科技集团股份有限公司 董事会 一、基本情况 2023年2月10日，广东省工业和信息化厅下发关于《广东省工业和信息化厅关 于公布2022年度专精特新中小企业和2019年到期复核通过企业名单的通告》，公司 被认定为广东省2022年度专精特新中小企业，有效期为2022年至2025年。 二、对公司的影响 本次入选广东省2022年度专精特新中小企业，是对公司创新能力、专业化程 度、专注动物造血营养产业核心领域及发展前景的充分认可及肯定，是公司综合 实力的体现，将有助于提高公司品牌知名度、核心竞争力和市场影响力，有利于 公司在新产品研发和新技术方面的储备，对公司经营发展具有积极作用。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及 ...

证券代码：838275 证券简称：驱动力 公告编号：2023-004 A 董事、监事、高级管理人员每年解除限售 B 离职董事、监事、高级管理人员解除限售 C 自愿限售解除限售 D 限制性股票解除限售 广东驱动力生物科技集团股份有限公司股票解除限售公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、本次股票解除限售数量总额为 1,254,749 股，占公司总股本 0.783%，可交 易时间为 2023 年 2 月 10 日。 | | | | 是否为控 | 董事、监 | | | 本次解 除限售 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 股东姓名 | 股股东、 | 事、高级 | 本次解限 | 本次解除 | 股数占 | 尚未解除 | | | 序号 | | 实际控制 | | | 限售登记 | | 限售的股 | | | | 或名称 | 人或其一 | 管理人员 | 售原因 | 股票数量 | 公司总 | 票数量 | | | ...

证券代码：838275 证券简称：驱动力 公告编号：2023-003 广东驱动力生物科技集团股份有限公司 关于预计 2023 年日常性关联交易的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、 日常性关联交易预计情况 （一） 预计情况 单位：元 | 关联交易类别 | 主要交易内容 | 预计 | 2023 年 | （2022）年与关联 | 预计金额与上年实际发 | | --- | --- | --- | --- | --- | --- | | | | | 发生金额 | 方实际发生金额 | 生金额差异较大的原因 | | 购买原材料、 | 原材料采购 | | 800,000 | 574,535 | 无 | | 燃料和动力、 | | | | | | | 接受劳务 | | | | | | | 销售产品、商 | | | | | | | 品、提供劳务 | | | | | | | 委托关联方销 | | | | | | | 售产品、商品 | | | | | | | 接受关联方委 | | | | | | | 托代为 ...

广东驱动力生物科技集团股份有限公司 第三届监事会第九次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2023 年 1 月 10 日 2.会议召开地点：公司会议室 3.会议召开方式：现场 4.发出监事会会议通知的时间和方式：2022 年 12 月 30 日 以纸质及电话方式发 出 5.会议主持人：全渺晶 证券代码：838275 证券简称：驱动力 公告编号：2023-002 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《关于预计 2023 年度日常性关联交易》的议案 1.议案内容： 2023 年度公司日常性关联交易预计金额不超过 80 万元。 2.议案表决结果：同意 3 票；反对 0 票；弃权 0 票。 3.回避表决情况 本议案无需回避表决 本议案无需提交股东大会审议。 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开符合《公司法》、《公司章程》的相关规定。 （二）会议出席情况 ...

华安证券股份有限公司 关于广东驱动力生物科技集团股份有限公司 2023 年日常性关联交易预计的专项核查意见 华安证券股份有限公司（以下简称"华安证券"或"保荐机构"）为广东驱动力 生物科技集团股份有限公司（以下简称"驱动力"或"公司"）股票向不特定合格投 资者公开发行的保荐机构。根据《证券发行上市保荐业务管理办法》《北京证券 交易所证券发行上市保荐业务管理细则》等有关规定，对驱动力关联交易的事项 发表专项意见如下： 一、关联交易概述 2023 年 1 月 10 日，驱动力第三届董事会第九次会议审议通过了《关于预计 2023 年度公司日常性关联交易的议案》，根据公司经营发展规划，对 2023 年的 日常性关联交易进行了预计。具体预计金额如下： （一）购买原材料及劳务 1、公司预计向广东新南都饲料科技有限公司及其子公司翁源县新南都饲料 科技有限公司采购原材料，预计 2023 年采购金额不超过 80 万元。 （二）销售商品及劳务 无 （三）其他 无 二、关联方基本情况及关联关系 1、广东新南都饲料科技有限公司 注册资本：1,077 万人民币 实缴资本：1,077 万元人民币 成立日期：2006 年 2 月 21 日 ...

证券代码：838275 证券简称：驱动力 公告编号：2023-001 广东驱动力生物科技集团股份有限公司 第三届董事会第九次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 2.会议召开地点：公司会议室 3.会议召开方式：现场 4.发出董事会会议通知的时间和方式：2022 年 12 月 30 日以纸质和电话方式 发出 5.会议主持人：刘平祥 6.会议列席人员：全渺晶、曾秋丽、程龙梅、刘焕良、时春华 7.召开情况合法、合规、合章程性说明： 会议召开符合《公司法》等法律、法规及本公司章程的有关规定 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2023 年 1 月 10 日 公司现任独立董事黄文锋、习欠云对本项议案发表了同意的独立意见。 3.回避表决情况： 本议案无需回避表决 4.提交股东大会表决情况： （二）会议出席情况 会议应出席董事 5 人，出席和授权出席董事 5 人。 二、议案审议情况 （一）审议通过《关于预计 2023 年度日常性关联交易》的议案 1.议案内容： 202 ...

公司董事会审议《关于预计 2023 年度日常性关联交易的议案》事项前，公 司已将相关材料递交独立董事审阅，我们对有关情况进行了认真的核查，认为公 司与关联方开展的业务属于公司正常经营行为，与关联方交易的价格按照市场公 允价格确定，不存在损害公司和中小股东利益的行为。 综上，我们同意将上述事项提交公司董事会审议。 （二）独立意见 公司预计 2023 年日常性关联交易，履行了必要的审批程序，符合《北京证 券交易所股票上市规则（试行）》等相关法律法规的要求，采取的定价政策合理， 价格公允，不存在损害股东利益的情况。 证券代码：838275 证券简称：驱动力 公告编号：2022-004 广东驱动力生物科技集团股份有限公司 独立董事关于第三届董事会第九次会议相关事项的 事前认可意见及独立意见 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 广东驱动力生物科技集团股份有限公司（以下简称"公司"或"驱动力"）于2023 年 1 月 10 日召开了第三届董事会第九次会议。根据相关法律法规及《独立董事 工作制度》等有关规 ...

Financial Performance - Operating revenue for the first nine months of 2022 was approximately CNY 106.03 million, an increase of 8.68% year-on-year[15]. - Net profit attributable to shareholders decreased by 52.47% to approximately CNY 14.58 million[15]. - Basic earnings per share for the first nine months of 2022 were CNY 0.09, down 60.87% from the previous year[15]. - Revenue for Q3 2022 was approximately CNY 41.80 million, a 9.78% increase compared to Q3 2021[15]. - Net profit for Q3 2022 was approximately CNY 8.43 million, a decrease of 17.90% year-on-year[15]. - The net profit attributable to shareholders for the first nine months of 2022 was CNY 14.58 million, a decrease of 52.47% year-on-year, while the net profit after deducting non-recurring items was CNY 8.14 million, down 69.22%[18]. - The total profit for Q3 2022 was CNY 9,143,257.18, a decline of 24.5% compared to CNY 12,074,394.59 in Q3 2021[49]. - The company's gross profit margin for Q3 2022 was approximately 56.9%, compared to 62.3% in Q3 2021[52]. - The company's retained earnings decreased to ¥31,003,398.28 from ¥34,198,819.23, a decline of about 9.3%[45]. Assets and Liabilities - Total assets as of September 30, 2022, were approximately CNY 262.94 million, a decrease of 5.43% compared to the end of the previous year[15]. - The company reported a debt-to-asset ratio of 7.68% on a consolidated basis, up from 5.04% at the end of the previous year[15]. - The company's total assets as of September 30, 2022, amounted to CNY 262.23 million, a decrease of 5.43% year-on-year, primarily due to a reduction in cash and receivables[17]. - The total liabilities increased to CNY 19,937,426.00 from CNY 13,576,301.94, marking an increase of approximately 47.5%[40]. - The total assets of Guangdong Drive Biological Technology Group as of September 30, 2022, amounted to CNY 262,940,945.83, a decrease from CNY 277,276,529.02 at the end of 2021[38]. - The company's cash and cash equivalents were CNY 10,859,972.12, down from CNY 32,399,560.97 at the end of 2021, indicating a significant liquidity reduction[38]. - The accounts receivable decreased to CNY 33,044,155.03 from CNY 39,036,068.40, reflecting a decline of approximately 15.4%[38]. - The company's inventory decreased to ¥7,955,963.12 from ¥9,298,984.81, reflecting a reduction of about 14.4%[44]. Cash Flow - Cash flow from operating activities increased significantly by 7,762.57% to approximately CNY 36.52 million[15]. - The net cash flow from operating activities for the first nine months of 2022 was CNY 36,517,064.14, compared to CNY 464,441.59 in the same period of 2021, indicating a substantial improvement[56]. - Cash inflow from operating activities for the first nine months of 2022 was CNY 132,651,880.32, a significant increase from CNY 88,685,470.29 in the same period of 2021, marking a growth of approximately 49.6%[56]. - Cash outflow from investing activities for the first nine months of 2022 totaled CNY 261,578,579.41, compared to CNY 249,128,553.60 in 2021, reflecting an increase of about 5%[56]. - The net cash flow from investing activities for the first nine months of 2022 was -CNY 22,077,489.40, an improvement from -CNY 35,848,541.90 in the same period of 2021[56]. - Cash inflow from financing activities amounted to 56,226,400.00, with no new borrowings or bond issuances reported[60]. - Cash outflow for financing activities was 35,599,626.59, up from 20,786,002.39 in the previous period[60]. - The net increase in cash and cash equivalents was -21,072,265.77, compared to a slight increase of 378,653.20 previously[60]. Dividends and Shareholder Information - The company distributed cash dividends of CNY 34.11 million during the reporting period, impacting retained earnings[17]. - The proposed dividend distribution for the third quarter is CNY 0.80 per 10 shares, with no stock bonus or capital increase planned[35]. - The total number of ordinary shares at the end of the reporting period was 160,277,600 shares, with 5,054 shareholders[24]. - The stock option plan for 2022 involved granting 1,887,914 options to 32 individuals, with an exercise price set at CNY 4.61 per option[36]. Research and Development - The company is focused on developing new products and technologies in the feed additive sector to enhance nutritional value and improve animal health[6]. - The company is focusing on market expansion through the introduction of new products aimed at cost reduction and efficiency improvement for downstream industries[18]. - Research and development expenses for Q3 2022 were CNY 907,325.24, slightly down from CNY 948,143.14 in Q3 2021[52]. Other Financial Metrics - Non-recurring gains and losses totaled CNY 7.55 million for the reporting period, with a net amount of CNY 6.44 million after tax[21]. - The company’s weighted average return on equity was 3.47% for the reporting period, down from 4.04% in the previous year[19]. - The company incurred a credit impairment loss of CNY 1,553,916.12 in Q3 2022, compared to a loss of CNY 431,120.48 in Q3 2021[49]. - The company reported a significant increase in other income to ¥37,665.00 in Q3 2022 from ¥520,000.00 in Q3 2021, indicating a change in revenue sources[48]. - Basic and diluted earnings per share for Q3 2022 were both CNY 0.16, up from CNY 0.05 in Q3 2021, representing a 220% increase[53].

Product Development and Innovation - The company launched a new product "Xuexue Wang" which received the "Yue Brand" certification[4] - The company has obtained 1 new invention patent for a method of preparing L-Alany-L-Glutamine[4] - The company obtained a new invention patent for a method of preparing L-phenylalanine-L-glutamine, enhancing its R&D capabilities[34] - The company established the Animal Health Digital Research Institute and launched a new product on January 8, 2022[5] - The company is actively developing blood and related derivative products to improve animal health and disease resistance[14] - The company focuses on health blood products, including "Xie Xue Su," "Xie Xue Wang," and "Xie Xue Le," which are designed to enhance animal health and performance[22] - The company has established a blood nutrition R&D center to improve animal health and disease resistance[87] Market Expansion and Strategy - The company is focusing on expanding its product range to cover aquaculture and ruminants, aiming to reduce reliance on a single animal sector[13] - The company aims to expand its market presence by increasing awareness of blood nutrition among aquaculture farmers[16] - The company plans to expand its product range to include aquatic and ruminant animal markets to mitigate risks from single species epidemics[86] - The company launched new products aimed at cost reduction and efficiency improvement for the downstream industry, which are currently in the market expansion and user cultivation phase[38] Financial Performance - The company reported a revenue of CNY 64,232,221.91, an increase of 7.98% compared to the same period last year[28] - The net profit attributable to shareholders decreased by 69.87% to CNY 6,147,419.47, down from CNY 20,401,064.78 in the previous year[28] - The gross profit margin dropped significantly to 20.35% from 50.78% year-on-year[28] - Total assets decreased by 10.22% to CNY 248,944,043.71 compared to the end of the previous year[29] - The company achieved a net cash flow from operating activities of CNY 27,011,084.65, a substantial increase of 342.72% year-on-year[30] - The company’s weighted average return on equity decreased to 2.36% from 8.38% year-on-year[28] - The company’s total liabilities increased by 4.61% to CNY 14,621,331.51 compared to the previous year[29] Shareholder and Ownership Structure - The actual controller holds a total of 57.5153% of the company's shares, with Liu Jinping and Liu Pingxiang directly holding 33.2348% and 21.9104% respectively[14] - The total share capital of the company is 160,277,600 shares[23] - The company reported a total shareholding of 124,376,786 shares, representing 77.60% of the total shares outstanding[127] - Major shareholders include Liu Jinping with 54,868,015 shares (34.23%) and Liu Pingxiang with 35,117,429 shares (21.91%)[127] Risks and Challenges - The company is facing risks from market competition due to counterfeit products that may affect its brand image[13] - The company has not experienced any significant changes in major risks during the reporting period[14] - The company has not identified any delisting risks[14] Corporate Governance and Compliance - The company has ensured compliance with legal regulations regarding information disclosure, maintaining accuracy and completeness[98] - The actual controller has committed to not occupying company funds and avoiding any related party transactions outside of normal business operations[102] - The company has committed to ensuring that any economic losses arising from the rental of factory premises will be fully compensated by the actual controlling shareholders[103] Employee and Community Engagement - The company added 23 new employees, contributing to local employment stability[83] - The company donated living supplies to the COVID-19 prevention command in Guangzhou Baiyun District in 2022[83] - The total number of employees increased from 74 to 76, with a net addition of 24 employees during the reporting period[152] Research and Development - The company is enhancing its R&D capabilities by collaborating with well-known universities and research institutes[13] - Research and development expenses rose by 9.87% to $2,293,360.29, reflecting the company's focus on developing new products[61][63] Stock and Financing Activities - The company initiated a stock option incentive plan for 2022[4] - The company repurchased 900,000 shares, accounting for 0.56% of the total share capital, with a total payment of approximately ¥6.06 million[96] - The company has committed to avoiding any form of competition with its actual controller, ensuring no similar business activities are undertaken[99] Economic Contributions - The company contributed approximately RMB 600,000 in taxes to national and local governments during the reporting period[83]

Group 1: Research and Development - The company has a good cash flow and is continuously increasing R&D investment, having launched multiple specialized research projects this year [3] - In 2022, the company added 1 new invention patent and launched several new products, including Xuexue Milk (for ruminants) and organic aloe [4] - The company has developed products that effectively degrade mold in feed materials and enhance blood oxygen levels, improving feed utilization and reducing health costs [4] Group 2: Market Expansion and Product Applications - The company is expanding its applications in the ruminant field and is actively planning to enter the aquaculture sector [3] - The main business focus is on developing, producing, and selling feed additives that enhance animal blood production capabilities [4] - The company has achieved significant results in improving non-specific immunity against seasonal swine fever and has made breakthroughs in treating blue ear disease through blood production technology [4] Group 3: Capital Market Plans - Since its listing on the Beijing Stock Exchange, the company is learning relevant regulations and will consider stock issuance or convertible bonds for acquisitions if suitable targets arise [3]